Ramucirumab and durvalumab for previously treated, advanced non –small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)

Emerging evidence supports combining immune checkpoint inhibitors (ICIs) with conventional or targeted therapies to enhance ICI antitumour activity and broaden the spectrum of patients who respond to ICIs. Here, we present the safety and preliminary efficacy of ramucirumab, an anti-VEGFR2 IgG1, plus durvalumab, an anti –PD-L1 IgG1, in previously treated patients with advanced non–small-cell lung cancer (NSCLC), gastric/gastro-oesophageal junction adenocarcinoma (gastric/GEJ), or hepatocellular carcinoma (HCC).

Source: European Journal of Cancer - August 18, 2020 Category: Cancer & Oncology Authors: Yung-Jue Bang, Talia Golan, Laetitia Dahan, Siqing Fu, Victor Moreno, Keunchil Park, Ravit Geva, Filippo De Braud, Zev A. Wainberg, Martin Reck, Laura Goff, Naomi Laing, Gu Mi, Joana M. Oliveira, Heather Wasserstrom, Chia-Chi Lin Tags: Original Research Source Type: research